If You're Taking NMN and Your Numbers Haven't Moved, Stop Blaming the Brand. A 2016 Paper Explains What's Actually Eating It.

If you are reading this, your protocol is probably tight. NMN dosed and timed. TMG paired. Resveratrol sourced from a brand with published COAs. You have listened to the Sinclair interviews, read the Attia breakdowns, and built a stack based on the best available evidence. You have also, most likely, watched your data refuse to move — and spent months assuming the problem was execution.

It is not execution. It is the model.

There are three things wrong with the standard oral NAD+ protocol that no supplement brand has an incentive to tell you. The first is an enzyme. The second is a measurement problem. The third is a timing variable. Each one alone is enough to explain why your protocol isn't working. Together, they make oral NAD+ supplementation after 40 structurally unreliable — regardless of product quality, dose, or stack composition.

The enzyme is CD38. The measurement problem is that blood NAD+ levels do not predict tissue NAD+ levels. The timing variable is that NAD+ oscillates up to 53% across your circadian cycle, and no brand has built a protocol around when to deliver it.

Three structural failures. No supplement brand has an incentive to tell you about any of them.

The paper that changed the conversation on the first problem was published in Cell Metabolism in 2016.

Its subject was CD38 — part of the immune system's cellular signalling apparatus, present in virtually every tissue in the body. CD38's primary function is not NAD+ metabolism. But as a secondary function, it degrades NAD+. And according to the 2016 research, CD38 activity approximately doubles between the ages of 20 and 50.

The implication, worked out carefully across the paper and confirmed in subsequent research published in Nature Metabolism in 2020, was significant: the majority of age-related NAD+ decline is not caused by the body producing less NAD+. It is caused by the body destroying it faster. The drain is the mechanism. The production side is a secondary issue.

For a category of consumer who had spent years listening to David Sinclair and Andrew Huberman and Peter Attia discuss NAD+ precursors — NMN, NR, the full protocol stack — this finding reframed everything. The question was not how to fill the tank more efficiently. The question was what was emptying it.

Daniel, 47, is a product architect in Amsterdam. He has been tracking his health data for six years. Oura ring. DEXA scan annually. Full bloodwork panel every six months. He found the longevity research community through Huberman's podcast in 2021 and began NMN supplementation that same year.

He is not an outlier. In the longevity forums where serious self-experimenters compare notes — threads running to hundreds of replies, thousands of views, maintained across years — the pattern is consistent. Sophisticated buyers with verified product and solid protocols who cannot move their markers.

"At some point," Daniel said, "you have to stop assuming the problem is execution. The problem might be the model."

THE CD38 PROBLEM

To understand why Daniel's protocol was failing, it helps to understand what CD38 actually does.

CD38 is an enzyme. Enzymes are proteins that catalyse — accelerate — specific biochemical reactions. CD38 catalyses a reaction that consumes NAD+ as its substrate. When CD38 is active, NAD+ disappears. When CD38 activity is low, NAD+ persists. When CD38 activity doubles — as it does between ages 20 and 50, according to the published research — the rate at which your body destroys NAD+ increases dramatically.

The 2016 Cell Metabolism paper established this mechanism by comparing NAD+ levels in normal mice against CD38-knockout mice — animals genetically modified to produce no CD38. The CD38-knockout mice maintained NAD+ levels comparable to young animals as they aged. The normal mice showed the standard steep decline. CD38 was not a contributing factor to NAD+ decline. It was, according to the researchers, the dominant factor.

Subsequent work by Chini et al., published in Nature Metabolism in 2020, reinforced this finding in human tissue and extended it. The conclusion was that CD38-driven NAD+ degradation is not a minor variable to account for. It is the primary engine of the decline that every longevity protocol is trying to address.

Here is what that means in practical terms.

When you take an oral NMN or NR supplement, the best-case scenario is this: a fraction of the precursor survives gut degradation, enters systemic circulation, undergoes enzymatic conversion into NAD+, and arrives at the tissue level. The losses at each step are significant — researchers estimate that oral bioavailability for NAD+ precursors is substantially lower than the label dose suggests, and those losses compound with age as gut conversion capacity declines.

But even in a world where all of that worked perfectly — where every milligram of NMN you swallowed arrived intact at the cellular level — you would still be introducing that NAD+ into a tissue environment where CD38 activity has doubled. You are filling a tank with the drain wide open, and the drain is getting faster every year.

This is why the data was not moving for Daniel. This is why the forums are full of people who did everything right and got nothing.

THE SECOND LAYER: SIRT3, CIRCADIAN RHYTHM, AND WHAT ACTUALLY DEPENDS ON NAD+

The CD38 drain is the mechanism most supplement brands do not discuss. But for people following this research seriously, the downstream effects of NAD+ depletion are equally important to understand.

NAD+ is the substrate for a family of enzymes called sirtuins. There are seven sirtuin variants. Three are directly relevant to the conversation about aging.

SIRT1 regulates metabolic function and circadian rhythm. It is the sirtuin most studied in longevity research and the one most frequently discussed in the Sinclair and Huberman material. SIRT1 activity is NAD+-dependent. When NAD+ is low, SIRT1 activity falls. When SIRT1 activity falls, your circadian clock loses fidelity — the internal timing mechanism that regulates sleep architecture, cortisol rhythm, and metabolic cycling becomes less precise.

SIRT3 operates exclusively inside the mitochondria. It is the only sirtuin directly linked to human longevity in centenarian research. It regulates mitochondrial efficiency — the quality of cellular energy production. SIRT3, like all sirtuins, requires NAD+ to function. When NAD+ is depleted, SIRT3 activity falls. Mitochondrial efficiency degrades. The cell has less fuel. Every energy-intensive process in the body — cognition, physical recovery, immune response — operates on thinner margin.

SIRT6 maintains genomic stability. It repairs DNA strand breaks. NAD+-dependent.

This is the system that is running below capacity when CD38 activity has doubled and oral supplement delivery has failed to compensate. Not one function. Not one symptom. The whole network.

Daniel, when he finally read the CD38 research, described it as "the explanation I had been missing for two years. The model I was working from was wrong. I was trying to outrun a drain I didn't know existed."

WHY FORMAT IS THE VARIABLE THAT CHANGES THE EQUATION

The implication of the CD38 problem for supplementation strategy is not that NAD+ precursors are worthless. It is that the margin for error on delivery format is narrow.

If you are getting significant losses at the oral conversion stage, and you are simultaneously dealing with an active CD38-driven drain at the tissue level, the amount of functional NAD+ actually arriving where it needs to be becomes very small. Oral precursors may be delivering a fraction of what the label promises into a cellular environment that is actively destroying what does arrive.

This is the argument that has shifted serious self-experimenters toward direct delivery formats. Not because injection is more convenient or more fashionable. Because when you understand the full mechanism — the conversion losses on the oral side and the CD38 drain on the cellular side — the arithmetic of oral supplementation becomes very difficult to make work for adults over 40.

Subcutaneous injection bypasses the oral conversion chain. The molecule enters systemic circulation as NAD+, not as a precursor awaiting conversion. It does not require gut health to survive. It does not require enzymatic conversion to become functional. It arrives having lost none of itself to digestion.

It still faces the CD38 environment. Every format does. But it arrives in enough quantity, with none of the conversion losses, that it can meaningfully elevate circulating NAD+ levels despite the drain. The injection does not stop CD38 from functioning. It delivers enough that the drain becomes a known variable to manage rather than a hidden mechanism that makes the whole exercise futile.

A PROTOCOL BUILT AROUND THE ACTUAL MECHANISM

NADPure is a subcutaneous injection pen containing high-purity NAD+ in powder form — the same format used in clinical-grade biologics worldwide. It is designed for at-home use, without clinical supervision. The pen ships as dry powder and is activated at point of use: sterile solution is added, mixed for approximately 30 seconds, and loaded into the pen before application. This ensures the NAD+ enters your body as a freshly activated compound, not a solution that has been degrading in transit.

Each pen is batch-verified. Independent laboratory certificates of analysis are available on request, not behind a marketing badge. Ships with a silicone cool-pack — no dry ice required, no refrigeration needed on receipt. Store up to 25°C, away from direct sunlight. Use within 45 days of mixing.

The dose is precise. The molecule is not a precursor. There is no conversion step. It is NAD+ delivered as NAD+.

The protocol is designed to be maintained. NAD+ levels return toward baseline over approximately four weeks without continued supplementation — this is the biology of a molecule with a short half-life in the body, not dependency. For people who understand the CD38 mechanism and the systemic role NAD+ plays across sirtuin function, circadian regulation, and cellular energy production, this is not a reason to avoid the protocol. It is a reason to treat it as what it is: cellular maintenance, not a supplement cycle.

Among users who have switched from oral NMN or NR protocols, the reported pattern is consistent with what the mechanism would predict. Not placebo-level variation. Measurable changes — sleep quality, recovery, cognitive baseline, afternoon energy plateau — that did not appear after months of oral supplementation and arrived within weeks of switching format.